Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma

International Journal of Cancer

Volumn 74, Issue 3, 1997, Pages 346-358

  Manne, Upender ^a   Myers, Russell B ^a   Moron, Cecilia ^a   Poczatek, Robert B ^a   Dillard, Stephenie ^a   Weiss, Heidi ^b   Brown, David ^b   Srivastava, Sudhir ^c   Grizzle, William E ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CELL GROWTH; CELL PROLIFERATION; COLORECTAL CANCER; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROGNOSIS;

AGED; CELL NUCLEUS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030791861     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970620)74:3<346::AID-IJC19>3.0.CO;2-9     Document Type: Article

References (74)

1. AUVINEN, A., ISOLA, J., VISAKORPI, T., KOIVULA, T., VIRTANEN, S. and HAKAMA, M., Overexpression of p53 and long-term survival in colon carcinoma. Brit. J. Cancer, 70, 293-296 (1994).
2. BAAS, I.O., MULDER, J.R., OFFERHAUS, J.A., VOGELSTEIN, B. and HAMILTON, S.R., An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J. Pathol., 172, 5-12 (1994).
3. BAAS, I.O., VAN DEN BERG, F.M., MULDER, J.R., CLEMENT, M.J., SLEBOS, R.J.C., HAMILTON, S.R. and OFFERHAUS, J.A., Potential false-positive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms. J. Pathol., 178, 264-267 (1996).
4. BARETTON, G.B., DIEBOLD, J., CHRISTOFORIS, G., VOGT, M., MULLER, C., DOPFER, K., SCHNEIDERBANGER, K., SCHMIDT, M. and LOHRS, U., Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Cancer, 77, 255-264 (1996).
5. BARETTON, G.B., VOGT, M., DIEBOLD, J., SCHNEIDERBANGER, K. and SCHMIDT, M., Prognostic significance of p53 expression, chromosome 17 copy number, and DNA ploidy in non-metastasized colorectal carcinomas (stages IB and II). Scand. J. Gastroenterol., 31, 48.1-489 (19966).
6. BEAHRS, O.H., HENSON, D.E., HUTTER, R.V.P. and MYERS, M.H., Manual for staging of cancer/American Joint Committee on Cancer (4th ed.), pp. 75-79, Lippincott, Philadelphia (1992).
7. BELL, S.M., SCOTT, N., CROSS, D., SAGAR, P., LEWIS, F.A., BLAIR, G.E., TAYLOR, G.R., DIXON, M.F. and QUIRKE, P., Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gasiroenterology, 104, 57-64 (1993).
8. BELLUCO, C., GUILLEM, J.G., KEMENY, N., HUANG, Y., KLIMSTRA, D., BERGER, M.F. and COHEN, A.M., p53 nuclear protein overexpression in colorectal cancer. A dominant predictor of survival in patients with advanced hepatic metastases. J. clin. Oncol., 14, 2696-2701 (1996).
9. BILIM, V., TOMITA, Y., KAWASAKI, T., KATAGIRI, A., IMAI, T., TAKEDA, M. and TAKAHASHI, K., Prognostic value of Bcl-2 and p53 expression in urinary tract transitional cell cancer. J. nat. Cancer Inst., 88, 686-688 (1996).
10. BOSARI, S., MONEGHINI, L., GRAZIANI, D., LEE, A.K., MURRAY, J.J., COGGI, G. and VIALE, G.M., Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum. Pathol., 26, 534-540 (1995).
11. BOSARI, S., VIALE, G., BOSSI, P., MAGGIONI, M., COGGI, G., MURRAY, J.J. and LEE, A.K.C., Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J. nat. Cancer Inst., 86, 681-687 (1994).
12. COX, D.R., Regression models and life tables. J. Roy. Stat. Soc., 34, 187-220 (1972).
13. CUNNINGHAM, J., LUST, J.A., SCHAID, D.J., BREN, G.D., CARPENTER, H.A., RIZZA, E., KOVACH, J.S. and THIBODEAU, S.N., Expression of p53 and 17p allelic loss in colorectal adenocarcinoma. Cancer Res., 52, 1974-1980 (1992).
14. DELATTRE, O., LAW, D.J., REMVIKOS, Y., SASTRE, X., FEINBERG, A.P., OLSCHWANG, S., MÉLOT, T., SALMON, R.J., VALIDIRE, P. and THOMAS, G., Multiple genetic alterations in distal and proximal colorectal cancer. Lancet, ii, 353 (1989).
15. DIX, B.R., ROBBINS, P., SOONG, R., JENNER, D., HOUSE, A.K., IACOPETA, B.J., BELL, R., CLARKE, G., FAULKNER, C.K., KERMODE, I.D., LEVITT, K.M. and SMITH, P., The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int. J. Cancer, 59, 749-751 (1994).
16. FEARON, E.R. and VOGELSTEIN, B., A genetic model for colorectal tumorigenesis. Cell, 61, 759-767 (1990).
17. FINLAY, C.A., HINDS, P.W., TAN, T.H., ELIYAHU, D., OREN, M. and LEVINE, A.J., Activating mutations for transformation by p53 produce a gene product that forms an hsc 700-p53 complex with an altered half-life. Mol. Cell Biol., 8, 531-539 (1988).
18. FLAMINI, G., CURIGLIANO, G., RATTO, C., ASTONE, A., FERRETTI, G., NUCERA, P., SOFO, L., SGAMBATO, A., BONINSEGNA, A., CRUCITTI, F. and CITTADINI, A., Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis. Europ. J. Cancer, 32A, 802-806 (1996).
19. FLEISS, J.L., Statistical methods for rates and proportions, J. Wiley, New York (1981).
20. FLOHIL, C.C., JANSSEN, P.A. and BOSMAN, F.T., Expression of Bcl-2 protein in hyperplastic polyps, adenomas, and carcinomas of the colon. J. Pathol., 178, 393-397 (1996).
21. GOH, H.-S., JOCELYN, Y. and SMITH, D.R., p53 point mutations and survival in colorectal cancer patients. Cancer Res., 55, 5217-5221 (1995).
22. GORCZYCA, W., MARKIEWSKI, M., KRAM, A., TUZIAK, T. and DOMAGALA, W., Immunohistochemical analysis of Bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction. Virchows Arch., 420, 229-233 (1995).
23. GREWAL, H., GUILLEM, J.G., KLIMSTRA, D.S. and COHEN, A.M., p53 nuclear overexpression may not be an independent prognostic marker in early colorectal cancer. Dis. Colon Rectum, 38, 1176-1181 (1995).
24. GRIZZLE, W.E., MYERS, R.B., ARNOLD, M.M. and SRIVASTAVA, S., Evaluation of biomarkers in breast and prostate cancer. J. cell. Biochem. (Suppl.), 19, 259-266 (1994).
25. GRIZZLE, W.E., MYERS, R.B., MANNE, U. and SRIVASTAVA, S., Immunohistochemical evaluation of biomarkers in prostatic and colorectal neoplasia. Methods mol. Biol. (1996) (In press).
26. GRIZZLE, W.E., MYERS, R.B. and OELSCHLAGER, D.K., Prognostic biomarkers in breast cancer: factors affecting immunohistochemical evaluation. Breast. 1, 243-250 (1995).
27. HAGUE, A., MOORGHEN, M., HICKS, D., CHAPMAN, M. and PARASKEVA, C., Bcl-2 expression in human colorectal adenomas and carcinomas. Oncogene, 9, 3367-3370 (1994).
28. HAMELIN, R., LAURENT-PUIG, P., OLSCHWANG, S., JEGO, N., ASSELAIN, B., REMVIKOS, Y., GIRODET, J., SALMON, R.J. and THOMAS, G., Association of p53 mutations with short survival in colorectal cancer. Gastroenterology, 106, 42-48 (1994).
29. HENRIKSEN, R., WILANDER, E. and OBERG, K., Expression and prognostic significance of Bcl-2 in ovarian tumors. Brit. J. Cancer, 72, 1324-1329 (1995).
30. HENSON, D.E., Loss of p53-immunostaining intensity breast cancer. J. nat. Cancer Inst., 88, 1015-1016 (1996).
31. HOCKENBERRY, D., NUNEZ, G., MILLIMAN, C., SCHNEIBER, R.D. and KORSMFYER, S.J., Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond.), 348, 334-336 (1990).
32. HOLLSTEIN, M., SIDRANSKY, D., VOGELSTEIN, B. and HARRIS, C.C., p53 mutations in human cancers. Science. 253, 49-53 (1991).
33. IONOV, V. PEINADO, M., MALKHOSYAN, S., SHIBATA, D. and PERUCHO, M., Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature (Lond.), 363, 558-561 (1993).
34. JACOBS, T.W., PRIOLEAU, J.E., STILLMAN, I.E. and SCHNITT, S.J., Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J. nat. Cancer Inst., 88, 1054-1059 (1996).
35. JOENSUU, H., PYLKKANEN, L. and TOIKKANEN, S., Bcl-2 protein expression and long-term survival in breast cancer. Amer. J. Pathol., 145, 1191-1198 (1994).
36. KAKLAMANIS, L., SAVAGE, A., MORTENSEN, N., TSIOTOS, P., DOUSSIS-ANAGNOSTOPOULOU, I., BIDDOLPH, S., WHITEHOUSE, R., HARRIS, A.L. and GATTER, K.C., Early expression of bcl-2 protein in the adenoma-carcinoma sequence of colorectal neoplasia. J. Pathol., 179, 10-14 (1996).
37. KAPLAN, E.L. and MEIER, P., Non-parametric estimation from incomplete observations. J. Amer. Stat. Assoc., 53, 457-481 (1958).
38. KERN, S.E., FEARON, E.R., TERSMETTE, K.W.F., ENTERLINE, J.P., LEPPERT, M., NAKAMURA, Y., WHITE, R., VOGELSTEIN, B., HAMILTON, S.R., Clinical and pathological associations with allelic loss in colorectal carcinomas. J. Amer. med. Assoc., 261, 3099-31003 (1989).
39. KIM, Y.-W., LEE, S., PARK, J.-H., YOON, T.-N., PARK, J.-K. and YANG, M.-H., An immunohistochemical study of the expression of p53 protein in colon cancer. J. Korean med. Sci., 10, 176-182 (1995).
40. KOBAYASHI, M., WATANABE, H., AJIOKA, Y., YOSHIDA, M., HITOMI, J. and ASAKURA, H., Correlation of p53 protein expression with apoptotic incidence in colorectal neoplasia. Virchows Arch., 427, 27-32 (1995).
41. KORSMEYER, S., Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood, 80, 879-886 (1992).
42. KRESSNER, U.L.F., LINDMARK, G., GERDIN, B., PAHLMAN, L. and GLIMELIUS, B., Immunohistochemical p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res., 16, 951-958 (1996).
43. LANZA, G., MAESTRI, I., DUBINI, A., GAFA, R., SANTINI, A., FERRETTI, S. and CAVAZZINI, L., p53 expression in colorectal cancer, relation to tumor type, DNA ploidy pattern, and short-term survival. Amer. J. clin. Pathol., 105, 604-612 (1996).
44. LEVIN, A.J., MOMAND, J., and FINLAY, A.C., The p53 tumor suppressor gene. Mature (Land.), 351, 453-456 (1991).
45. LIPPONEN, P., PIETILAINEN, T., KOSMA, V.-M., AALTOMAA, S., ESKELINEN, M. and SYRJANEN, K., Apoptosis suppressing protein Bcl-2 is expressed in well-differentiated breast carcinomas with favorable prognosis. J. Pathol., 177, 49-55 (1995).
46. MULDER, J.-W.R., BASS, I.O., POLAK, M.M., GOODMAN, S.N. and OFFERHAUS, G.J.A., Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Brit. J. Cancer, 71, 1257-1262 (1995).
47. MYERS, R.B., LAMPEJO, O., HERRERA, G.A., SRIVASTAVA, S., OELSCHLAGER, D., BROWN, D.A., WATERBOR, J.A. and GRIZZLE, W.E., TGF-alpha expression is a relatively late event in the progression of prostatic adenocarcinoma. J. Urol. Pathol., 3, 195-204 (1995).
48. MYERS, R.B., OELSCHLAGER, D., SRIVASTAVA, S. and GRIZZLE, W.E., Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas. Prostate, 25, 243-248 (1994).
49. NAKAMURA, T., SAKAI, T. and NARIYA, S., Cell death in colorectal polyps as evaluated by in situ 3-tailing reaction and its relationship to Bcl-2 expression. Pathol. Int., 45, 721-728 (1995).
50. NATHANSON, S.D., LINDEN, M.D., TENDER, P., ZARBO, R., JACOBSON, G. and NELSON, L.S., Relationship among p53, stage, and prognosis of large bowel cancer. Dis. Colon Rectum, 37, 527-534 (1994).
51. O'CONNELL, M.J., SCHAID, D.J., GANJU, V., CUNNINGHAM, J., KOVACH, J.S. and THIBODEAU, S.N., Current status of adjuvant chemotherapy for colorectal cancer. Cancer. 70, 1732-1739 (1992).
52. OFNER, D., MAIER, H., RIEDMANN, B., HOLZBERGER, P., NAGLER, M., TOTSCH, M., BANKFALVI, A., WINDE, G., BOCKER, W. and SCHMID, K.W., Immunohistochemicaliy detectable p53 and mdm-2 oncoprotein expression in colorectal carcinoma: prognostic significance. J. clin. Pathol. mol. Pathol. 48, M12-M16 (1995a).
53. OFNER, D., RIEHEMANN, K., MAIER, H., RIEDMANN, B., NEHODA, H., TOTSCH, M., BOCKER, W., JASANI, B. and SCHMID, K.W., Immunohistochemically detectable Bcl-2 expression in colorectal carcinoma: correlation with tumor stage and patient survival. Brit. J. Cancer. 72, 981-985 (1995).
54. PARKER, S.L., TONG, T., BOLDEN, S. and WINGO, P.A., Cancer statistics, 1997. CA Cancer J. Clin., 47, 5-27 (1997).
55. PEINADO, M.A., FERNANDEZ-RENART, M., CAPELLA, G., WILSON, L. and PERUCHO, J., Mutations in the p53 suppressor gene do not correlate with c-K-ras oncogene mutations in colorectal cancer. Int. J. Oncol., 2, 123-134 (1993).
56. PIRIS, M. and 14 OTHERS, p53 and Bcl-2 expression in high grade B-cell lymphomas: correlation with survival time. Brit. J. Cancer. 69, 337-341
57. REMVIKOS, Y. TOMINAGA, O., HAMMEL, P., LAURENT-PUIG, P., SALMON, R.J., DUTRILLAUX, B. and THOMAS, G., Increased p53 protein content of colorectal tumors correlates with poor survival. Brit. J. Cancer. 66, 758-764 (1992).
58. SCHNEIDER, B.C., HILSEBECK, S.G., HENSEL, C.H., PEKKEL, V., SHELTON, C.H., RODRIQIEZ-MARTINEZ, H.A., GUTIERREZ-DIAZ, M.E.C., PULITZER, D.R. and ALLRED, D.C., p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos. Virchows Arch., 424, 187-193 (1994).
59. SCOTT, N.P., SAGER, P., STEWART, J., BLAIR, G.E., DIXON, M.F. and QUIRKE, P., p53 in colorectal cancer: clinicopathological correlations and prognostic significance. Brit. J. Cancer. 63, 317-319 (1991).
60. SILVESTRINI, R., VENERONI, S., DAIDONE, M.G., BENINI, E., BORACCHI, P., MEZETTI, M., DI FRONZO, G., RILKE, F. and VERONESI, U., The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. nat. Cancer Inst., 86, 499-504 (1994).
61. SINICROPE, F.A., RUAN, S.B., CLEARY, K.R., STEPHENS, L.C., LEE, J.J. and LEVIN, B., Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res., 55, 237-241 (1995).
62. SMITH, D.R. and GOH, H.S., p53 and prognosis in colorectal cancer. Ann. Acad. Med. Singapore, 25, 107-112 (1996).
63. SMITH, D.R., JI, C.-Y. and GOH, H.S., Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Brit. J. Cancer, 74, 216-223 (1996).
64. STARZYNSKA, T., BROMLEY, M., GHOSH, A. and STERN, P.L., Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Brit. J. Cancer, 66, 558-562 (1992).
65. SUN, X.-F., CARSTENSEN, J.M., ZHANG, H., STAL, O., WINGREN, S., HATSCHEK, T. and NORDENSKJOLD, B., Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet, 340, 1369-1373 (1992).
66. THIBODEAU, S.N., BREN, G. and SCHAID, D., Microsatellite instability in cancer of the proximal colon. Science. 260, 816-819 (1993).
67. TOMODA, H. and KAKEJI, Y., Immunohistochemical analysis of p53 in colorectal cancer regarding clinicopathological correlation and prognostic significance. J. Surg. Oncol., 58, 125-128 (1995).
68. WAF/CIP1 in breast epithelial cells. Cancer Res., 55, 4520-4524 (1995).
69. VIALE, G., RONCALLI, M., GLIMELIUS, L., GRAZIANI, D., JOHANSSON, H., BERGHOLM, U. and COGGI, G., Prognostic value of Bcl-2 immunoreactivity in medullary thyroid carcinoma. Hum. Pathol., 26, 945-950 (1995).
70. WATSON, A.J.M., MERRITT, A.J., JONES, L.S., ASKEW, J.N., ANDERSON, E., BECCIOLINI, A., BALZI, M., POTTEN, C.S. and HICKMAN, J.A., Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Brit. J. Cancer. 73, 889-895 (1996).
71. YAMAGUCHI, A., KUROSAKA, Y., FUSHIDA, S., KANNO, M., YONEMURA, Y., MIWA, K. and MIYAZAKI, I., Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer. 70, 2778-2784 (1992).
72. YAMAGUCHI, A., NAKAGAWARA, G., KUROSAKA, Y., NISHIMURA, G., YONEMURA, Y. and MIYAZAKI, I., p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer and its prognostic significance. Brit. J. Cancer, 68, 399-401 (1993).
73. YONISCH-ROUACH, E., RESNITZKY, D., LOTEM, J., SACHS, L., KIMCHI, A. and OREN, M., Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (Lond.), 352, 345-347 (1991).
74. ZENG, Z.H., SARKIS, A.S., ZHANG, Z.-F., KLIMSTRA, D.S., CHAMYTONOWICZ, E., GUILLEM, J.G., CORDON-CARDO, C. and COHEN, A.M., p53 nuclear overexpression: an independent predictor of survival in lymph node-positive colorectal cancer patients. J. clin. Oncol., 12, 2043-2050 (1994).